{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:37:41Z","timestamp":1781800661839,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,9,13]],"date-time":"2010-09-13T00:00:00Z","timestamp":1284336000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1038\/aps.2010.109","type":"journal-article","created":{"date-parts":[[2010,9,13]],"date-time":"2010-09-13T09:25:44Z","timestamp":1284369944000},"page":"1350-1358","source":"Crossref","is-referenced-by-count":57,"title":["Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a \u201cWestern-style diet\u201d by increasing PPAR \u03b1 and \u03b3 expression and reducing TC, MMP-9, and Cat S levels"],"prefix":"10.1038","volume":"31","author":[{"given":"Yan-wen","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-qiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-ya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,13]]},"reference":[{"key":"BFaps2010109_CR1","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1097\/00005344-200212000-00007","volume":"40","author":"TM Lee","year":"2002","unstructured":"Lee TM, Chou TF, Tsai CH . Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin f2alpha formation. J Cardiovasc Pharmacol 2002; 40: 868\u201374.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFaps2010109_CR2","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1161\/01.CIR.103.6.836","volume":"103","author":"J Sundstr\u00f6m","year":"2001","unstructured":"Sundstr\u00f6m J, Lind L, Vessby B, Andr\u00e9n B, Aro A, Lithell H . Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later. Circulation 2001; 103: 836\u201341.","journal-title":"Circulation"},{"key":"BFaps2010109_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1161\/hq0302.105287","volume":"22","author":"JH Wu","year":"2002","unstructured":"Wu JH, Hagaman J, Kim S, Reddick RL, Maeda N . Aortic constriction exacerbates atherosclerosis and induces cardiac dysfunction in mice lacking apolipoprotein E. Arterioscler Thromb Vasc Biol 2002; 22: 469\u201375.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFaps2010109_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.neurobiolaging.2004.06.018","volume":"26","author":"YX Wang","year":"2005","unstructured":"Wang YX . Cardiovascular functional phenotypes and pharmacological responses in apolipoprotein E deficient mice. Neurobiol Aging 2005; 26: 309\u201316.","journal-title":"Neurobiol Aging"},{"key":"BFaps2010109_CR5","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1172\/JCI13350","volume":"108","author":"M Takemoto","year":"2001","unstructured":"Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001; 108: 1429\u201337.","journal-title":"J Clin Invest"},{"key":"BFaps2010109_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbalip.2004.11.004","volume":"1687","author":"A Planavila","year":"2005","unstructured":"Planavila A, Laguna JC, V\u00e1zquez-Carrera M . Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation. Biochim Biophys Acta 2005; 1687: 76\u201383.","journal-title":"Biochim Biophys Acta"},{"key":"BFaps2010109_CR7","first-page":"365","volume":"9","author":"P Ye","year":"2006","unstructured":"Ye P, Sheng L, Zhang C, Liu Y . Atorvastatin attenuating down-regulation of peroxisome proliferator-activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo. J Pharm Pharm Sci 2006; 9: 365\u201375.","journal-title":"J Pharm Pharm Sci"},{"key":"BFaps2010109_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1161\/01.RES.0000177090.07296.ac","volume":"97","author":"V Senthil","year":"2005","unstructured":"Senthil V, Chen SN, Tsybouleva N, Halder T, Nagueh SF, Willerson JT, et al. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res 2005; 97: 285\u201392.","journal-title":"Circ Res"},{"key":"BFaps2010109_CR9","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.2337\/db07-0924","volume":"57","author":"E Caglayan","year":"2008","unstructured":"Caglayan E, Stauber B, Collins AR, Lyon CJ, Yin F, Liu J, et al. Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. Diabetes 2008; 57: 2470\u20139.","journal-title":"Diabetes"},{"key":"BFaps2010109_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ahj.2008.01.035","volume":"156","author":"V Rold\u00e1n","year":"2008","unstructured":"Rold\u00e1n V, Mar\u00edn F, Gimeno JR, Ruiz-Espejo F, Gonz\u00e1lez J, Feliu E, et al. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am Heart J 2008; 156: 85\u201391.","journal-title":"Am Heart J"},{"key":"BFaps2010109_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1161\/01.HYP.0000242331.99369.2f","volume":"48","author":"XW Cheng","year":"2006","unstructured":"Cheng XW, Obata K, Kuzuya M, Izawa H, Nakamura K, Asai E, et al. Elastolytic cathepsin induction\/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension 2006; 48: 979\u201387.","journal-title":"Hypertension"},{"key":"BFaps2010109_CR12","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/FJC.0b013e31817ae60f","volume":"51","author":"AP Singh","year":"2008","unstructured":"Singh AP, Singh M, Balakumar P . Effect of mast cell stabilizers in hyperhomocysteinemia-induced cardiac hypertrophy in rats. J Cardiovasc Pharmacol 2008; 51: 596\u2013604.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFaps2010109_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1161\/01.ATV.14.1.133","volume":"14","author":"Y Nakashima","year":"1994","unstructured":"Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R . ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994; 14: 133\u201340.","journal-title":"Arterioscler Thromb"},{"key":"BFaps2010109_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/cvr\/cvn001","volume":"78","author":"PJ Smeets","year":"2008","unstructured":"Smeets PJ, Teunissen BE, Willemsen PH, van Nieuwenhoven FA, Brouns AE, Janssen BJ, et al. Cardiac hypertrophy is enhanced in PPAR alpha\u2212\/\u2212 mice in response to chronic pressure overload. Cardiovasc Res 2008; 78: 79\u201389.","journal-title":"Cardiovasc Res"},{"key":"BFaps2010109_CR15","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1161\/hc4001.097186","volume":"104","author":"K Yamamoto","year":"2001","unstructured":"Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K . Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 2001; 104: 1670\u20135.","journal-title":"Circulation"},{"key":"BFaps2010109_CR16","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1161\/01.RES.0000179226.34112.6d","volume":"97","author":"SZ Duan","year":"2005","unstructured":"Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM . Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res 2005; 97: 372\u20139.","journal-title":"Circ Res"},{"key":"BFaps2010109_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.bcp.2007.07.004","volume":"75","author":"JD Raffetto","year":"2008","unstructured":"Raffetto JD, Khalil RA . Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75: 346\u201359.","journal-title":"Biochem Pharmacol"},{"key":"BFaps2010109_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/00041552-200403000-00008","volume":"13","author":"B L\u00f3pez","year":"2004","unstructured":"L\u00f3pez B, Gonz\u00e1lez A, D\u00edez J . Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. Curr Opin Nephrol Hypertens 2004; 13: 197\u2013204.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"BFaps2010109_CR19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.7150\/ijbs.3.385","volume":"3","author":"BC Henderson","year":"2007","unstructured":"Henderson BC, Sen U, Reynolds C, Moshal KS, Ovechkin A, Tyagi N, et al. Reversal of systemic hypertension-associated cardiac remodeling in chronic pressure overload myocardium by ciglitazone. Int J Biol Sci 2007; 3: 385\u201392.","journal-title":"Int J Biol Sci"},{"key":"BFaps2010109_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2353\/ajpath.2008.071126","volume":"173","author":"XW Cheng","year":"2008","unstructured":"Cheng XW, Murohara T, Kuzuya M, Izawa H, Sasaki T, Obata K, et al. Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol 2008; 173: 358\u201369.","journal-title":"Am J Pathol"},{"key":"BFaps2010109_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0002-9440(10)63114-8","volume":"164","author":"XW Cheng","year":"2004","unstructured":"Cheng XW, Kuzuya M, Sasaki T, Arakawa K, Kanda S, Sumi D, et al. Increased expression of elastolytic cysteine proteases, cathepsins S and K, in the neointima of balloon-injured rat carotid arteries. Am J Pathol 2004; 164: 243\u201351.","journal-title":"Am J Pathol"},{"key":"BFaps2010109_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00109-008-0423-2","volume":"87","author":"Q Tang","year":"2009","unstructured":"Tang Q, Cai J, Shen D, Bian Z, Yan L, Wang YX, et al. Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT\/GSK3beta signaling. J Mol Med 2009; 87: 249\u201360.","journal-title":"J Mol Med"},{"key":"BFaps2010109_CR23","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1080\/07853890310001294","volume":"35","author":"H Nakagami","year":"2003","unstructured":"Nakagami H, Jensen KS, Liao JK . A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med 2003; 35: 398\u2013403.","journal-title":"Ann Med"},{"key":"BFaps2010109_CR24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.phrs.2009.11.012","volume":"61","author":"A Rohini","year":"2010","unstructured":"Rohini A, Agrawal N, Koyani CN, Singh R . Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 2010; 61; 269\u201380.","journal-title":"Pharmacol Res"},{"key":"BFaps2010109_CR25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1161\/01.HYP.0000254415.31362.a7","volume":"49","author":"E Takimoto","year":"2007","unstructured":"Takimoto E, Kass DA . Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007; 49: 241\u20138.","journal-title":"Hypertension"},{"key":"BFaps2010109_CR26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/FJC.0b013e3181b76713","volume":"54","author":"BY Kang","year":"2009","unstructured":"Kang BY, Wang W, Palade P, Sharma SG, Mehta JL . Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. J Cardiovasc Pharmacol 2009; 54: 327\u201334.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFaps2010109_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejphar.2009.10.050","volume":"627","author":"EY Choi","year":"2010","unstructured":"Choi EY, Chang W, Lim S, Song BW, Cha MJ, Kim HJ, et al. Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh. Eur J Pharmacol 2010; 627: 56\u201362.","journal-title":"Eur J Pharmacol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps2010109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2010109","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2010109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:22:39Z","timestamp":1684412559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps2010109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,13]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["BFaps2010109"],"URL":"https:\/\/doi.org\/10.1038\/aps.2010.109","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,13]]}}}